Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Alternative Medicine and Oncology: Erroneous Biochemical Failure Following Herbal Supplementation in Early-Stage Prostate Cancer.

Abel S, Renz P, Hasan S, White R, Dawodu D, Wegner RE, Fuhrer R.

J Am Osteopath Assoc. 2019 Nov 1;119(11):763-767. doi: 10.7556/jaoa.2019.126.

PMID:
31657830
2.

Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.

Kollmeier MA, Stock RG, Stone N.

Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):645-53.

PMID:
14529768
3.

Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.

Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E.

Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):664-73.

PMID:
11849788
4.

More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.

Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.

PMID:
30843003
5.

Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.

Martinez AA, Kestin LL, Stromberg JS, Gonzalez JA, Wallace M, Gustafson GS, Edmundson GK, Spencer W, Vicini FA.

Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):343-52.

PMID:
10802358
6.

Prostate brachytherapy: treatment strategies.

Stone NN, Stock RG.

J Urol. 1999 Aug;162(2):421-6.

PMID:
10411050
7.

10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy.

Grimm PD, Blasko JC, Sylvester JE, Meier RM, Cavanagh W.

Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):31-40.

PMID:
11516848
8.
9.
10.

Outcomes after prostate brachytherapy are even better than predicted.

Frank SJ, Levy LB, van Vulpen M, Crook J, Sylvester J, Grimm P, Pugh TJ, Swanson DA.

Cancer. 2012 Feb 1;118(3):839-47. doi: 10.1002/cncr.26307. Epub 2011 Jul 12.

11.

Percentage of positive biopsy cores as predictor of clinical outcome in prostate cancer treated with radiotherapy.

Kestin LL, Goldstein NS, Vicini FA, Martinez AA.

J Urol. 2002 Nov;168(5):1994-9.

PMID:
12394693
12.

Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Adamovich E.

Urology. 2004 Oct;64(4):754-9.

PMID:
15491715
13.

Risk factors for biochemical recurrence after a tissue-ablative prostate-specific antigen <0.2 ng/mL.

Taussky D, Lambert C, Meissner N, Bahary JP, Delouya G.

Brachytherapy. 2018 Sep - Oct;17(5):794-798. doi: 10.1016/j.brachy.2018.05.011. Epub 2018 Jun 29.

PMID:
30153914
14.

Radical dose escalation by high-dose-rate brachytherapy for localized prostate cancer-Significance of prostate-specific antigen nadir level within 18 months as correlation for long-term biochemical control.

Schroeder C, Geiger F, Siebert FA, Baumann R, Bockelmann G, Schultze J, Kimmig B, Dunst J, Galalae R.

Brachytherapy. 2019 Jan - Feb;18(1):8-12. doi: 10.1016/j.brachy.2018.08.013. Epub 2018 Oct 25.

PMID:
30482622
15.

Biochemical (prostate-specific antigen) relapse-free survival and toxicity after 125I low-dose-rate prostate brachytherapy.

Khaksar SJ, Laing RW, Henderson A, Sooriakumaran P, Lovell D, Langley SE.

BJU Int. 2006 Dec;98(6):1210-5. Epub 2006 Oct 11.

17.

Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.

Kupelian PA, Katcher J, Levin HS, Klein EA.

Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1043-52.

PMID:
9169811
18.

Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer.

Merrick GS, Butler WM, Galbreath RW, Lief JH.

Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):41-8.

PMID:
11516849
19.

Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy.

Cheung R, Tucker SL, Lee AK, de Crevoisier R, Dong L, Kamat A, Pisters L, Kuban D.

Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):993-1002.

PMID:
15752878
20.

Prostate-specific antigen spikes after permanent prostate brachytherapy.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Anderson RL.

Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):450-6.

PMID:
12243821

Supplemental Content

Support Center